Journal of Cutaneous Medicine and Surgery: Incorporating Medical and Surgical Dermatology

, Volume 6, Issue 6, pp 554–560

Imiquimod: A Review

  • Aditya K. Gupta
  • Melanie  Browne
  • Robyn  Bluhm

DOI: 10.1007/s10227-001-0134-6

Cite this article as:
Gupta, A., Browne, M. & Bluhm, R. JCMS (2002) 6: 554. doi:10.1007/s10227-001-0134-6

Background and Objective: Imiquimod (Aldara) is an immune response modifier used primarily to treat anogenital warts. Imiquimod induces cytokines and enhances cell-mediated cytolytic antiviral activity in vivo. It exhibits antiviral and antitumor effects; however, it does not exhibit direct antiviral effects in vitro. By inducing cytokines, such as interferon a, imiquimod stimulates both the innate immune response and the cellular arm of acquired immunity. Currently, imiquimod is approved for use in the treatment of external genital and perianal warts in adults. Conclusion: Beyond its established use, there are case reports and preliminary studies suggesting the effectiveness of imiquimod 5% cream in the treatment of nongenital human papillomavirus warts, molluscum contagiosum, actinic keratosis, basal cell carcinoma, squamous cell carcinoma, Bowen's disease, nongenital human papillomavirus infection, and vulvar intraepithelial neoplasia.

Copyright information

© 2002 Canadian Dermatology Associa tion

Authors and Affiliations

  • Aditya K. Gupta
    • 1
  • Melanie  Browne
    • 2
  • Robyn  Bluhm
    • 2
  1. 1.Division of Dermatology, Department of Medicine, Sunnybrook and Women's College Health Science Center (Sunnybrook site) and the University of Toronto, Toronto, CanadaCA
  2. 2.Mediprobe Laboratories Inc., Toronto, Ontario, CanadaCA